Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's "Critical Path" Leads To Pharmaceutical Science Advisory Committee Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

The committee will discuss research opportunities under FDA's "Critical Path" initiative. Other topics for the Oct. 19-20 meeting include manufacturing, the risk-based GMP initiative, parametrics and generic drug equivalence.
Advertisement

Related Content

FDA Seeks Input On GI Drug Bioequivalence Standards From Committee
FDA Seeks Input On GI Drug Bioequivalence Standards From Committee
FDA Moving Toward PAT Standardized Nomenclature And Definitions
Parametric Tolerance Interval Testing Working Group To Deliver Findings By Year-End
Agency Will Fund Research On Development Roadblocks; Orphan Drug Grants Are Model
Agency Will Fund Research On Development Roadblocks; Orphan Drug Grants Are Model

Topics

Advertisement
UsernamePublicRestriction

Register

PS060356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel